Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling

1 May 2025

Abstract excerpt

BACKGROUND: The gut microbiome influences the host immune system, cancer development and progression, as well as the response to immunotherapy during cancer treatment. Here, we analyse the composition of the gut bacteriome in metastatic Non-Small Cell Lung Cancer (NSCLC) patients receiving Pembrolizumab immunotherapy within a prospective maintenance trial through opportunistic sampling during treatment. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer Research and Treatments
Share to Gut microbiota and health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40356191
DOI: 10.1111/1759-7714.70075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic SamplingPMID 40356191Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity Read ↗

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read ↗

Systemic metabolic depletion of gut microbiome undermines responsiveness to melanoma immunotherapySemantic proximity Read ↗

Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces TogetherSemantic proximity Read ↗

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read ↗

Metagenomic Characterization of The Tracheobronchial Microbiome in Lung CancerSemantic proximity Read ↗

Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung CancerSemantic proximity Read ↗

Identification and characterization of four bacteriome- and mycobiome-derived subtypes in tumour and adjacent mucosa tissue of colorectal cancer patientsSemantic proximity Read ↗

Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Systemic Metabolic Depletion of Intestine Microbiome Undermines Melanoma Immunotherapy EffectivenessSemantic proximity Read ↗

A pan-cancer analysis of the microbiome in metastatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.